{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:10:31Z","timestamp":1793909431919,"version":"4.8.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31700297"],"award-info":[{"award-number":["31700297"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Key Research and Development Program of Xianyang","award":["L2023-ZDYF-SF-017)"],"award-info":[{"award-number":["L2023-ZDYF-SF-017)"]}]},{"name":"Changzhou Sci. & Tech. Program","award":["CJ20200045"],"award-info":[{"award-number":["CJ20200045"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Chemistry"],"DOI":"10.1186\/s13065-025-01689-7","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T11:14:54Z","timestamp":1764155694000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Mechanism-informed identification of FDA-approved topoisomerase inhibitors disrupting SARS-CoV-2 nucleocapsid\u2013RNA interactions"],"prefix":"10.1186","volume":"19","author":[{"given":"Da-Wei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Shuang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangxu","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"issue":"10223","key":"1689_CR1","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497\u2013506.","journal-title":"Lancet"},{"issue":"8","key":"1689_CR2","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727\u201333.","journal-title":"N Engl J Med"},{"issue":"4","key":"1689_CR3","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.imj.2023.08.005","volume":"2","author":"MA Islam","year":"2023","unstructured":"Islam MA. A review of SARS-CoV-2 variants and vaccines: viral properties, mutations, vaccine efficacy, and safety. Infect Med. 2023;2(4):247\u201361.","journal-title":"Infect Med"},{"issue":"7","key":"1689_CR4","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1038\/s41591-022-01816-0","volume":"28","author":"O Puhach","year":"2022","unstructured":"Puhach O, Adea K, Hulo N, Sattonnet P, Genecand C, Iten A, Jacqu\u00e9rioz F, Kaiser L, Vetter P, Eckerle I, Meyer B. Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, delta or Omicron SARS-CoV-2. Nat Med. 2022;28(7):1491\u2013500.","journal-title":"Nat Med"},{"issue":"1","key":"1689_CR5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3390\/v15010167","volume":"15","author":"S Chatterjee","year":"2023","unstructured":"Chatterjee S, Bhattacharya M, Nag S, Dhama K, Chakraborty C. A detailed overview of SARS-CoV-2 omicron: its sub-variants, mutations and pathophysiology, clinical characteristics, immunological landscape, immune escape, and therapies. Viruses. 2023;15(1):167.","journal-title":"Viruses"},{"issue":"3","key":"1689_CR6","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41579-020-00468-6","volume":"19","author":"P V\u2019kovski","year":"2021","unstructured":"V\u2019kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2021;19(3):155\u201370.","journal-title":"Nat Rev Microbiol"},{"issue":"19","key":"1689_CR7","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S. Lopez de Castilla D. Remdesivir for the treatment of Covid-19\u2014Final report. N Engl J Med. 2020;383(19):1813\u201326.","journal-title":"N Engl J Med"},{"issue":"6575","key":"1689_CR8","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1126\/science.abl4784","volume":"374","author":"DR Owen","year":"2021","unstructured":"Owen DR, Allerton CM, Anderson AS, Aschenbrenner L, Avery M, Berritt S, Boras B, Cardin RD, Carlo A, Coffman KJ, Dantonio A. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science. 2021;374(6575):1586\u201393.","journal-title":"Science"},{"issue":"3","key":"1689_CR9","first-page":"178","volume":"21","author":"JM Minkoff","year":"2023","unstructured":"Minkoff JM, tenOever B. Innate immune evasion strategies of SARS-CoV-2. Nat Rev Microbiol. 2023;21(3):178\u201394.","journal-title":"Nat Rev Microbiol"},{"issue":"Pt 2","key":"1689_CR10","doi-asserted-by":"publisher","first-page":"135201","DOI":"10.1016\/j.ijbiomac.2024.135201","volume":"279","author":"YA El-Maradny","year":"2024","unstructured":"El-Maradny YA, Badawy MA, Mohamed KI, Ragab RF, Moharm HM, Abdallah NA, Elgammal EM, Rubio-Casillas A, Uversky VN, Redwan EM. Unraveling the role of the nucleocapsid protein in SARS-CoV-2 pathogenesis: from viral life cycle to vaccine development. Int J Biol Macromol. 2024;279(Pt 2):135201.","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"1689_CR11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12985-023-01968-6","volume":"20","author":"W Wu","year":"2023","unstructured":"Wu W, Cheng Y, Zhou H, Sun C, Zhang S. The SARS-CoV-2 nucleocapsid protein: its role in the viral life cycle, structure and functions, and use as a potential target in the development of vaccines and diagnostics. Virol J. 2023;20(1):6.","journal-title":"Virol J"},{"issue":"6","key":"1689_CR12","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.3390\/v13061115","volume":"13","author":"Z Bai","year":"2021","unstructured":"Bai Z, Cao Y, Liu W, Li J. The SARS-CoV-2 nucleocapsid protein and its role in viral structure, biological functions, and a potential target for drug or vaccine mitigation. Viruses. 2021;13(6):1115.","journal-title":"Viruses"},{"issue":"20","key":"1689_CR13","doi-asserted-by":"publisher","first-page":"e105938","DOI":"10.15252\/embj.2020105938","volume":"39","author":"Y Peng","year":"2020","unstructured":"Peng Y, Du N, Lei Y, Dorje S, Qi J, Luo T, Gao GF, Song H. Structures of the SARS-CoV\u20102 nucleocapsid and their perspectives for drug design. EMBO J. 2020;39(20):e105938.","journal-title":"EMBO J"},{"key":"1689_CR14","doi-asserted-by":"crossref","unstructured":"Cubuk J, Alston JJ, Incicco JJ, Singh S, Stuchell-Brereton MD, Ward MD, Zimmerman MI, Vithani N, Griffith D, Wagoner JA, Bowman GR. 2021. The SARS-CoV-2 nucleocapsid protein is dynamic, disordered, and phase separates with RNA. Nat Commun. 12, 1936.","DOI":"10.1038\/s41467-021-21953-3"},{"key":"1689_CR15","doi-asserted-by":"publisher","first-page":"940756","DOI":"10.3389\/fimmu.2022.940756","volume":"13","author":"F Rashid","year":"2022","unstructured":"Rashid F, Xie Z, Suleman M, Shah A, Khan S, Luo S. Roles and functions of SARS-CoV-2 proteins in host immune evasion. Front Immunol. 2022;13:940756.","journal-title":"Front Immunol"},{"key":"1689_CR16","doi-asserted-by":"publisher","first-page":"1195871","DOI":"10.3389\/fimmu.2023.1195871","volume":"14","author":"DP Maison","year":"2023","unstructured":"Maison DP, Deng Y, Gerschenson M. SARS-CoV-2 and the host-immune response. Front Immunol. 2023;14:1195871.","journal-title":"Front Immunol"},{"issue":"1","key":"1689_CR17","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1038\/s41598-024-53906-3","volume":"14","author":"F Edalat","year":"2024","unstructured":"Edalat F, Khakpour N, Heli H, Letafati A, Ramezani A, Hosseini SY, Moattari A. Immunological mechanisms of the nucleocapsid protein in COVID-19. Sci Rep. 2024;14(1):3711.","journal-title":"Sci Rep"},{"issue":"31","key":"1689_CR18","doi-asserted-by":"publisher","first-page":"eabp9770","DOI":"10.1126\/sciadv.abp9770","volume":"8","author":"AD L\u00f3pez-Mu\u00f1oz","year":"2022","unstructured":"L\u00f3pez-Mu\u00f1oz AD, Kosik I, Holly J, Yewdell JW. Cell surface SARS-CoV-2 nucleocapsid protein modulates innate and adaptive immunity. Sci Adv. 2022;8(31):eabp9770.","journal-title":"Sci Adv"},{"key":"1689_CR19","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1038\/s41467-021-22297-8","volume":"12","author":"M Zhao","year":"2021","unstructured":"Zhao M, Yu Y, Sun LM, Xing JQ, Li T, Zhu Y, Wang M, Yu Y, Xue W, Xia T, Cai H. GCG inhibits SARS-CoV-2 replication by disrupting the liquid phase condensation of its nucleocapsid protein. Nat Commun. 2021b;12:2114.","journal-title":"Nat Commun"},{"key":"1689_CR20","doi-asserted-by":"publisher","first-page":"199221","DOI":"10.1016\/j.virusres.2023.199221","volume":"336","author":"I Boniardi","year":"2023","unstructured":"Boniardi I, Corona A, Basquin J, Basquin C, Milia J, Nagy I, Tramontano E, Zinzula L. Suramin inhibits SARS-CoV-2 nucleocapsid phosphoprotein genome packaging function. Virus Res. 2023;336:199221.","journal-title":"Virus Res"},{"issue":"3","key":"1689_CR21","doi-asserted-by":"publisher","first-page":"e01186","DOI":"10.1128\/spectrum.01186-23","volume":"11","author":"A Royster","year":"2023","unstructured":"Royster A, Ren S, Ma Y, Pintado M, Kahng E, Rowan S, Mir S, Mir M. SARS-CoV-2 nucleocapsid protein is a potential therapeutic target for anticoronavirus drug discovery. Microbiol Spectr. 2023;11(3):e01186\u201323.","journal-title":"Microbiol Spectr"},{"key":"1689_CR22","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.bbrc.2021.01.018","volume":"541","author":"M Dang","year":"2021","unstructured":"Dang M, Li Y, Song J. ATP biphasically modulates LLPS of SARS-CoV-2 nucleocapsid protein and specifically binds its RNA-binding domain. Biochem Biophys Res Commun. 2021;541:50\u20135.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"1689_CR23","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s42003-023-04480-3","volume":"6","author":"M Dang","year":"2023","unstructured":"Dang M, Li T, Song J. ATP and nucleic acids competitively modulate LLPS of the SARS-CoV2 nucleocapsid protein. Commun Biology. 2023;6(1):80.","journal-title":"Commun Biology"},{"issue":"9","key":"1689_CR24","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S2213-2600(21)00237-X","volume":"9","author":"J Aman","year":"2021","unstructured":"Aman J, Duijvelaar E, Botros L, Kianzad A, Schippers JR, Smeele PJ, Azhang S, Bartelink IH, Bayoumy AA, Bet PM, Boersma W. Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial. Lancet Respiratory Med. 2021;9(9):957\u201368.","journal-title":"Lancet Respiratory Med"},{"issue":"1","key":"1689_CR25","doi-asserted-by":"publisher","first-page":"2501743","DOI":"10.1080\/14756366.2025.2501743","volume":"40","author":"DW Zhang","year":"2025","unstructured":"Zhang DW, Xu XS, Xie L, Xu L, Fu Z, Li Y, Xu X. Natural product sennoside B disrupts liquid-liquid phase separation of SARS-CoV-2 nucleocapsid protein by inhibiting its RNA-binding activity. J Enzyme Inhib Med Chem. 2025;40(1):2501743.","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"6","key":"1689_CR26","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1093\/oxfordjournals.jbchem.a123972","volume":"112","author":"N Takeuchi","year":"1992","unstructured":"Takeuchi N, Nakamura T, Takeuchi F, Hashimoto E, Yamamura H. Inhibitory effect of Mitoxantrone on activity of protein kinase C and growth of HL60 cells. J Biochem. 1992;112(6):762\u20137.","journal-title":"J Biochem"},{"issue":"1","key":"1689_CR27","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1046\/j.1365-2141.1998.00520.x","volume":"100","author":"B Bellosillo","year":"1998","unstructured":"Bellosillo B, Colomer D, Pons G, Gil J. Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998;100(1):142\u20136.","journal-title":"Br J Haematol"},{"issue":"5","key":"1689_CR28","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1124\/dmd.106.013474","volume":"35","author":"S Vibet","year":"2007","unstructured":"Vibet S, Maheo K, Gore J, Dubois P, Bougnoux P, Chourpa I. Differential subcellular distribution of Mitoxantrone in relation to chemosensitization in two human breast cancer cell lines. Drug Metab Dispos. 2007;35(5):822\u20138.","journal-title":"Drug Metab Dispos"},{"key":"1689_CR29","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/BF00255476","volume":"8","author":"S Fujimoto","year":"1982","unstructured":"Fujimoto S, Ogawa M. Antitumor activity of Mitoxantrone against murine experimental tumors: comparative analysis against various antitumor antibiotics. Cancer Chemother Pharmacol. 1982;8:157\u201362.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"1689_CR30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jns.2004.04.017","volume":"223","author":"G Edan","year":"2004","unstructured":"Edan G, Morrissey S, Le Page E. Rationale for the use of Mitoxantrone in multiple sclerosis. J Neurol Sci. 2004;223(1):35\u20139.","journal-title":"J Neurol Sci"},{"issue":"2","key":"1689_CR31","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.antiviral.2011.12.001","volume":"93","author":"SE Altmann","year":"2012","unstructured":"Altmann SE, Smith AL, Dyall J, Johnson RF, Dodd LE, Jahrling PB, Paragas J, Blaney JE. Inhibition of Cowpox virus and Monkeypox virus infection by Mitoxantrone. Antiviral Res. 2012;93(2):305\u20138.","journal-title":"Antiviral Res"},{"issue":"9","key":"1689_CR32","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.3390\/biomedicines9091176","volume":"9","author":"PG de la Sota","year":"2021","unstructured":"de la Sota PG, Lorente E, Notario L, Mir C, Zaragoza O, L\u00f3pez D. Mitoxantrone shows in vitro, but not in vivo antiviral activity against human respiratory syncytial virus. Biomedicines. 2021;9(9):1176.","journal-title":"Biomedicines"},{"key":"1689_CR33","doi-asserted-by":"publisher","first-page":"114614","DOI":"10.1016\/j.biopha.2023.114614","volume":"162","author":"MS Ahmed","year":"2023","unstructured":"Ahmed MS, Farag AB, Boys IN, Wang P, Menendez-Montes I, Nguyen NU, Eitson JL, Ohlson MB, Fan W, McDougal MB, Mar K. FDA approved drugs with antiviral activity against SARS-CoV-2: from structure-based repurposing to host-specific mechanisms. Biomed Pharmacother. 2023;162:114614.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"1689_CR34","doi-asserted-by":"publisher","first-page":"6294","DOI":"10.1038\/s41598-022-10293-x","volume":"15","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Radvak P, Lee J, Xu Y, Cao-Dao V, Xu M, Zheng W, Chen CZ, Xie H, Ye Y. Mitoxantrone modulates a Heparan sulfate-spike complex to inhibit SARS-CoV-2 infection. Sci Rep. 2022;15(1):6294.","journal-title":"Sci Rep"},{"issue":"9","key":"1689_CR35","doi-asserted-by":"publisher","first-page":"5648","DOI":"10.1039\/D1RA07434B","volume":"12","author":"P Kumar","year":"2022","unstructured":"Kumar P, Bhardwaj T, Giri R. Mitoxantrone dihydrochloride, an FDA approved drug, binds with SARS-CoV-2 NSP1 C-terminal. RSC Adv. 2022;12(9):5648\u201355.","journal-title":"RSC Adv"},{"issue":"1","key":"1689_CR36","doi-asserted-by":"publisher","first-page":"5777","DOI":"10.1038\/s41467-023-41453-w","volume":"14","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, Tang W, Stancanelli E, Jung E, Syed Z, Pagadala V, Saidi L, Chen CZ, Gao P, Xu M, Pavlinov I. Host Heparan sulfate promotes ACE2 super-cluster assembly and enhances SARS-CoV-2-associated syncytium formation. Nat Commun. 2023;14(1):5777.","journal-title":"Nat Commun"},{"key":"1689_CR37","doi-asserted-by":"crossref","unstructured":"D\u2019Agostino VG, Sighel D, Zucal C, Bonomo I, Micaelli M, Lolli G, Provenzani A, Quattrone A, Adami V. Screening approaches for targeting ribonucleoprotein complexes: a new dimension for drug discovery. SLAS DISCOVERY: Advancing Life Sciences R&D. 2019, 24(3):314\u2009\u2013\u200931.","DOI":"10.1177\/2472555218818065"},{"issue":"3","key":"1689_CR38","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/0006-2952(81)90083-6","volume":"30","author":"J Kapuscinski","year":"1981","unstructured":"Kapuscinski J, Darzynkiewicz Z, Traganos F, Melamed MR. Interactions of a new antitumor agent, 1, 4-dihydroxy-5, 8-bis [[2-[(2-hydroxyethyl) amino]-ethyl] amino]-9, 10-anthracenedione, with nucleic acids. Biochem Pharmacol. 1981;30(3):231\u201340.","journal-title":"Biochem Pharmacol"},{"issue":"17","key":"1689_CR39","doi-asserted-by":"publisher","first-page":"6302","DOI":"10.1073\/pnas.83.17.6302","volume":"83","author":"J Kapuscinski","year":"1986","unstructured":"Kapuscinski J, Darzynkiewicz Z. Relationship between the Pharmacological activity of antitumor drugs ametantrone and Mitoxantrone (Novatrone) and their ability to condense nucleic acids. Proc Natl Acad Sci. 1986;83(17):6302\u20136.","journal-title":"Proc Natl Acad Sci"},{"issue":"5","key":"1689_CR40","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.chembiol.2009.03.009","volume":"16","author":"S Zheng","year":"2009","unstructured":"Zheng S, Chen Y, Donahue CP, Wolfe MS, Varani G. Structural basis for stabilization of the Tau pre-mRNA splicing regulatory element by novantrone (mitoxantrone). Chem Biol. 2009;16(5):557\u201366.","journal-title":"Chem Biol"},{"issue":"2","key":"1689_CR41","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1124\/jpet.115.228650","volume":"356","author":"BB Hasinoff","year":"2016","unstructured":"Hasinoff BB, Wu X, Patel D, Kanagasabai R, Karmahapatra S, Yalowich JC. Mechanisms of action and reduced cardiotoxicity of pixantrone; a topoisomerase II targeting agent with cellular selectivity for the topoisomerase II\u03b1 isoform. J Pharmacol Exp Ther. 2016;356(2):397\u2013409.","journal-title":"J Pharmacol Exp Ther"},{"issue":"9","key":"1689_CR42","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1080\/15384047.2015.1070979","volume":"16","author":"N Beeharry","year":"2015","unstructured":"Beeharry N, Di Rora AG, Smith MR, Yen TJ. Pixantrone induces cell death through mitotic perturbations and subsequent aberrant cell divisions. Cancer Biol Ther. 2015;16(9):1397\u2013406.","journal-title":"Cancer Biol Ther"},{"issue":"4","key":"1689_CR43","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.4049\/jimmunol.180.4.2696","volume":"180","author":"F Ubiali","year":"2008","unstructured":"Ubiali F, Nava S, Nessi V, Longhi R, Pezzoni G, Capobianco R, Mantegazza R, Antozzi C, Baggi F. Pixantrone (BBR2778) reduces the severity of experimental autoimmune myasthenia Gravis in Lewis rats. J Immunol. 2008;180(4):2696\u2013703.","journal-title":"J Immunol"},{"issue":"5","key":"1689_CR44","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nrc2607","volume":"9","author":"JL Nitiss","year":"2009","unstructured":"Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer. 2009;9(5):338\u201350.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"1689_CR45","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/FPC.0b013e32833ffb56","volume":"21","author":"CF Thorn","year":"2011","unstructured":"Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, Altman RB. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics. 2011;21(7):440\u20136.","journal-title":"Pharmacogenet Genomics"},{"issue":"3","key":"1689_CR46","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1200\/JCO.1986.4.3.425","volume":"4","author":"RJ Cersosimo","year":"1986","unstructured":"Cersosimo RJ, Hong WK. Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol. 1986;4(3):425\u201339.","journal-title":"J Clin Oncol"},{"key":"1689_CR47","doi-asserted-by":"publisher","first-page":"199164","DOI":"10.1016\/j.virusres.2023.199164","volume":"334","author":"Z Wang","year":"2023","unstructured":"Wang Z, Pan Q, Ma L, Zhao J, McIntosh F, Liu Z, Ding S, Lin R, Cen S, Finzi A, Liang C. Anthracyclines inhibit SARS-CoV-2 infection. Virus Res. 2023;334:199164.","journal-title":"Virus Res"},{"issue":"1","key":"1689_CR48","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3390\/pharmaceutics14010176","volume":"14","author":"PC Yu","year":"2022","unstructured":"Yu PC, Huang CH, Kuo CJ, Liang PH, Wang LH, Pan MY, Chang SY, Chao TL, Ieong SM, Fang JT, Huang HC. Drug repurposing for the identification of compounds with Anti-SARS-CoV-2 capability via multiple targets. Pharmaceutics. 2022;14(1):176.","journal-title":"Pharmaceutics"},{"issue":"1\u20133","key":"1689_CR49","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.molstruc.2011.06.013","volume":"1000","author":"S Charak","year":"2011","unstructured":"Charak S, Jangir DK, Tyagi G, Mehrotra R. Interaction studies of epirubicin with DNA using spectroscopic techniques. J Mol Struct. 2011;1000(1\u20133):150\u20134.","journal-title":"J Mol Struct"},{"issue":"3","key":"1689_CR50","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/smll.201502118","volume":"12","author":"PD Halley","year":"2016","unstructured":"Halley PD, Lucas CR, McWilliams EM, Webber MJ, Patton RA, Kural C, Lucas DM, Byrd JC, Castro CE. Daunorubicin-loaded DNA Origami nanostructures circumvent drug\u2010resistance mechanisms in a leukemia model. Small. 2016;12(3):308\u201320.","journal-title":"Small"},{"issue":"6","key":"1689_CR51","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1093\/nar\/gkab097","volume":"49","author":"H Ij\u00e4s","year":"2021","unstructured":"Ij\u00e4s H, Shen B, Heuer-Jungemann A, Keller A, Kostiainen MA, Liedl T, Ihalainen JA, Linko V. Unraveling the interaction between doxorubicin and DNA Origami nanostructures for customizable chemotherapeutic drug release. Nucleic Acids Res. 2021;49(6):3048\u201362.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"1689_CR52","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/AAC.01168-19","volume":"64","author":"N Wiedemar","year":"2020","unstructured":"Wiedemar N, Hauser DA, M\u00e4ser P. 100 years of Suramin. Antimicrob Agents Chemother. 2020;64(3):10\u2013128.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"1689_CR53","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.3390\/molecules28062534","volume":"28","author":"C Guo","year":"2023","unstructured":"Guo C, Xu H, Li X, Yu J, Lin D. Suramin disturbs the association of the N-terminal domain of SARS-CoV-2 nucleocapsid protein with RNA. Molecules. 2023;28(6):2534.","journal-title":"Molecules"},{"issue":"8","key":"1689_CR54","doi-asserted-by":"publisher","first-page":"e00900","DOI":"10.1128\/AAC.00900-20","volume":"64","author":"C Salgado-Benvindo","year":"2020","unstructured":"Salgado-Benvindo C, Thaler M, Tas A, Ogando NS, Bredenbeek PJ, Ninaber DK, Wang Y, Hiemstra PS, Snijder EJ, van Hemert MJ. Suramin inhibits SARS-CoV-2 infection in cell culture by interfering with early steps of the replication cycle. Antimicrob Agents Chemother. 2020;64(8):e00900\u201320.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1689_CR55","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s42003-023-04789-z","volume":"6","author":"PS Kwon","year":"2023","unstructured":"Kwon PS, Xu S, Oh H, Kwon SJ, Rodrigues AL, Feroz M, Fraser K, He P, Zhang F, Hong JJ, Linhardt RJ. Suramin binds and inhibits infection of SARS-CoV-2 through both Spike protein-heparan sulfate and ACE2 receptor interactions. Commun Biology. 2023;6(1):387.","journal-title":"Commun Biology"}],"container-title":["BMC Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13065-025-01689-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13065-025-01689-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13065-025-01689-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T06:03:51Z","timestamp":1767074631000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13065-025-01689-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1689"],"URL":"https:\/\/doi.org\/10.1186\/s13065-025-01689-7","relation":{},"ISSN":["2661-801X"],"issn-type":[{"value":"2661-801X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"18 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"322"}}